GlassScriptPhysician profile
Rodman M Taber
NPI 1265542153
$1,653.26
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $117 · 2021: $368 · 2022: $637 · 2023: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $144.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $536.72 | 2019-2023 | Myosure Tissue Removal Device, Acessa Provu System |
| Abbvie INC. | $366.94 | 2019-2022 | |
| Astellas Pharma US INC | $126.66 | 2019-2022 | |
| Aspira Women'S Health INC | $99.11 | 2022 | |
| Daiichi Sankyo INC. | $90.82 | 2021-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $62.73 | 2019-2023 | |
| Amag Pharmaceuticals, INC. | $58.95 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $51.86 | 2019-2023 | Gardasil 9 |
| Pfizer INC. | $50.61 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $42.22 | 2022-2023 | |
| Myovant Sciences INC. | $36.84 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $36.30 | 2022 | |
| Coloplast Corp | $36.04 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.85 | 2020 | |
| Ibsa Pharma INC. | $14.67 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $14.44 | 2023 | Nexplanon |
| Exeltis, USA INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodman Taber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.